LobbyingAcurx Pharmaceuticals lobbying by quarter
Acurx Pharmaceuticals ACXP's latest lobbying report covers Q2 2026, at $30K. The four quarters Q4 2025–Q3 2026 total $90K. Its first report covers Q4 2024; the issues it reports most are Budget/Appropriations and Defense.
Acurx PharmaceuticalsACXP
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $90K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2024
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2024 | $20K | 1 |
| Q1 2025 | $20K | 1 |
| Q2 2025 | $30K | 1 |
| Q3 2025 | $30K | 1 |
| Q4 2025 | $30K | 1 |
| Q1 2026 | $30K | 1 |
| Q2 2026 | $30K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Budget and appropriations$145K · 7 reports
- Defense$45K · 3 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES6 reports
- SENATE6 reports
- Navy, Dept of2 reports
- Defense Threat Reduction Agency (DTRA)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| Innovative Federal Strategies | $190K | 7 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | Innovative Federal Strategies | $30K |
| 04/20for Q1 | Innovative Federal Strategies | $30K |
| 01/20for Q4 2025 | Innovative Federal Strategies | $30K |
| 25/10/20for Q3 2025 | Innovative Federal Strategies | $30K |
| 25/07/18for Q2 2025 | Innovative Federal Strategies | $30K |
| 25/04/16for Q1 2025 | Innovative Federal Strategies | $20K |
| 25/01/20for Q4 2024 | Innovative Federal Strategies | $20K |
| 25/01/14for Q4 2024 | Innovative Federal Strategies | Under $5,000 |